Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus.

Authors:
Ying Hu
Ying Hu
East China University of Science and Technology
China

Chronic Dis Transl Med 2019 Mar 15;5(1):25-36. Epub 2019 Mar 15.

Department of Endocrinology, Lankenau Hospital, Main Line Health System, Wynnewood, PA 19096, USA.

Treatment intended to lower cardiovascular (CV) risk in patients with diabetes has always been a primary goal of diabetes treatment. Due to the subdued effects of reducing hemoglobin A1c (HbA1c) on macrovascular complications, controlling other CV risk factors such as hypertension and hyperlipidemia instead of hyperglycemia has been the mainstay treatment to improve CV outcome in patients with type 2 diabetes mellitus (T2DM) until recent years. This review is intended to summarize and compare the results from the available cardiovascular outcome trials (CVOTs) for the two classes of glucose lowering drug: sodium-glucose co-transporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1 RA). The results including the EMPA-REG, CANVAS program and DECLARE-TIMI 58 trials for SGLT2i, and the ELIXA, LEADER, SUSTAIN-6, EXSCEL and HARMONY trials for GLP-1 RA were summarized. The potential mechanisms of these CV beneficial effects and the optimal CV risk reduction treatment in patients with T2DM based on patient risk stratification and evidence from these CVOTs in real-world setting were discussed.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S2095882X183006
Publisher Site
http://dx.doi.org/10.1016/j.cdtm.2019.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449766PMC
March 2019
4 Reads

Publication Analysis

Top Keywords

cardiovascular risk
8
diabetes mellitus
8
type diabetes
8
patients type
8
risk
5
glucagon-like peptide-1
4
sodium-glucose co-transporter
4
sglt2i glucagon-like
4
co-transporter inhibitor
4
inhibitor sglt2i
4
receptor agonist
4
empa-reg canvas
4
canvas program
4
program declare-timi
4
including empa-reg
4
glp-1 including
4
drug sodium-glucose
4
agonist glp-1
4
peptide-1 receptor
4
cvots classes
4

Similar Publications